All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The Phase 3 confirmatory clinical trial titled, study will evaluate Bucillamine in Patients with Mild-Moderate COVID-19”, patients will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day Bucillamine 200 mg TID or placebo TID for up to 14 days.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The EAP for compassionate use is a multi-center, open label study of Bucillamine in hospitalized patients with severe COVID-19 and is being done to complement the Company’s Phase 3 COVID-19 study in the U.S.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: McGill University Health Centre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
Company’s Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19 received approval from the independent Institutional Review Board ("IRB") at Advarra, a premier IRB services company in North America.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
U.S. FDA approval to proceed with the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19, the Company has submitted its clinical trial protocol for independent Institutional Review Board approval.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
Revive Therapeutics has received FDA approval to proceed with the Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in mild-moderate COVID-19. The company will now expand the Phase 3 clinical trials in Asia-Pacific Countries and Canada.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LY-CoV555
Therapeutic Area: Infections and Infectious Diseases Product Name: LY3819253
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
The study will include up to 2,400 participants and assess the ability of LY-CoV555 to prevent infection of long-term care residents and facility staff who have been exposed to SARS-CoV-2, the virus that causes COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bucillamine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
The Phase 3 confirmatory clinical study is a multi-center, randomized, double-blind, placebo-controlled study of bucillamine in patients with mild-moderate COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Interferon a2b
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2020
Details:
Altum reports that in May 2020 management requested a pre-IND meeting with the FDA with the intent to discuss the planned development of AP-003 (Interferon Alpha-2b for inhalation) for the treatment of COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AntiCovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 11, 2020
Details:
BetterLife has amended terms of the agreement entered into on May 6, 2020 with Altum to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AP-003, a potential COVID-19 treatment.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
